Deans' stroke musings: Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: A meta-regression analysis

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, June 29, 2020

Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: A meta-regression analysis

You'll have to ask your doctor about using aspirin to prevent the clotting effects of COVID-19, but you can't listen to me, I'm not medically trained.

And out-of-date besides.

WHO reclassified stroke in 2006, now a neurological disease not cardiovascular disease?

Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: A meta-regression analysis

Nudy M, Cooper J, Ghahramani M, et al

American Journal of Medicine|June 26, 2020 Whether aspirin is more efficacious for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) as the baseline risk rises, was investigated via this meta-regression analysis. Researchers analyzed randomized controlled trials (RCTs) comparing aspirin with control for primary prevention as well as assessed ASCVD (composite of myocardial infarction and ischemic stroke) and major bleeding. Overall 12 RCTs with 963,829 patient-years of follow-up were found. Findings revealed that a decrease in ASCVD was achieved by using aspirin for primary prevention; however, its clinical significance is unlikely in view of the increase in bleeding. No increase in the treatment effect of aspirin was evident as ASCVD risk increased, as many hypothesize. There is no hint from these findings that use of aspirin for higher-risk primary prevention patients is beneficial. Read the full article on American Journal of Medicine.